Scientific publications

Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells

Aug 21, 2017 | Magazine: Scientific Reports

Serrano-Candelas E (1,2), Martínez-Aranguren R (3), Vega O (3), Gastaminza G (3), Bartra J (4), Audicana MT (5), Núñez-Córdoba JM (6), Algorta J (7), Valero A (4,8), Martin M (9,10), Ferrer M (11).


Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU).

OmAb's mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune urticaria where IgE involvement is not clear, suggesting the involvement of additional mechanisms of action.

In this study, we sought to investigate the ability of OmAb to inhibit mast cell and basophil degranulation induced by sera from CSU patients. For this purpose, we performed a comparison between the in vitro incubation of sera from CSU patients treated with OmAb and the in vivo administration of OmAb in a clinical trial.

We found that OmAb added in vitro to sera from CSU patients did not modify the ability of the sera to induce cell degranulation. Similarly, the sera from patients treated with OmAb in the context of the clinical trial who had a good clinical outcome maintained the capacity to activate mast cells and basophils.

Thus, we conclude that the beneficial activity of OmAb does not correlate with the ability of patient sera to induce cell degranulation.

CITATION  Sci Rep. 2017 Aug 21;7(1):8985. doi: 10.1038/s41598-017-09361-4